Here are the 10-K annual reports from Agentix Corp (AGTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGTX filings page.
Agentix Corp. is a clinical-stage biotech focused on peripherally acting cannabinoid CB1 antagonists for metabolic diseases such as type 2 diabetes, obesity and NAFLD. The company has two lead assets, AGTX-2004 and AGTX-2003, licensed from NHRI and RTI, with AGTX-2004 cleared by the FDA to begin a Phase 1 trial managed through its Australian subsidiary.
Agentix generated no revenue in the years ended March 31, 2026 and 2025 and reported a net loss of $485,636 for 2026, narrowing from $567,048. Cash was only $771 at March 31, 2026 against current liabilities of $3,596,282, contributing to an accumulated deficit of $7,007,164 and substantial doubt about its ability to continue as a going concern. Operating expenses were $445,187, including $125,079 in research and development and $252,036 in professional fees.
The company depends on related-party funding, including a $353,450 mezzanine secured note from an affiliate and over $2.3 million of related-party payables. Its stock trades on the OTC Pink under “AGTX”, with 40,066,951 common shares outstanding as of June 30, 2026 and no equity compensation plans or dividends. Internal controls over financial reporting and cybersecurity oversight are described as not effective, with no audit committee and significant material weaknesses.